GlassScriptPhysician profile
Andrew J Ward
NPI 1922233774
$995.48
in general payments reported to CMS, 2019-2025
19 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.38 · 2022: $121 · 2023: $219 · 2024: $378 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $329.96 | 2021-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $169.59 | 2023-2025 | Keytruda, Lynparza |
| Tempus Ai, INC | $77.15 | 2024-2025 | Xt Cdx |
| Abbvie INC. | $71.37 | 2022-2024 | |
| Promega Corporation | $58.72 | 2022 | |
| Genentech USA, INC. | $49.60 | 2024-2025 | Lunsumio, Columvi, Kadcyla |
| Janssen Pharmaceuticals, INC | $42.73 | 2023-2024 | Xarelto |
| Davol INC. | $28.93 | 2025 | |
| Teleflex LLC | $20.88 | 2024 | Quikclot |
| E.R. Squibb & Sons, L.L.C. | $18.03 | 2025 | Opdivo |
| Kerecis Limited | $17.50 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Celgene Corporation | $16.73 | 2024 | Reblozyl |
| Solventum Corporation | $16.47 | 2024 | Prevena, Prevena Restor Bellaform |
| Daiichi Sankyo INC. | $16.23 | 2024 | Enhertu |
| Seagen INC. | $14.49 | 2023 | Adcetris |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $13.29 | 2022 | |
| Janssen Biotech, INC. | $13.25 | 2022 | |
| Iovance Biotherapeutics, INC. | $12.45 | 2025 | Amtagvi |
| Rigel Pharmaceuticals, INC. | $8.11 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.